Uveitis – Talk Bio

Actionable Insights Powered by AI

Alumis Completes IPO, Raising $250 Million for Inflammation and Immunology Research

Alumis, IPO, Inflammation, Immunology, Biotech, TYK2 Inhibitor, Plaque Psoriasis, Uveitis, Lupus